While there appeared to be a trend toward elevated NRG1 levels and an increase in tumor shrinkage (Figure 4A), neither elevated NRG1 nor reduced ERBB3 expression predicted for response to duligotuzumab or against response to cetuximab (Figure 4B). This evidence concerns the gene ERBB3 and neoplasm.